Please assess the completion status of the following clinical trial:

Trial Title: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed, previously untreated, Ph-positive \[either t(9;22) and/or BCR-ABL positive\] B-precursor acute lymphoblastic leukemia;~* Age more than 18 years;~* Eligible to intensive chemotherapy, due to general health status;~* ECOG (Eastern Cooperative Oncology Group) performance status ≤2;~* Absence of significant liver disease, as defined by the following criteria: total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, alanine aminotransferase (ALT) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the liver is present, and aspartate aminotransferase (AST) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the liver is present;~* Adequate pancreatic function as defined by serum amylase and lipase ≤1.5 × ULN;~* Diagnostic sample of bone marrow (or peripheral blood with \>50% of blasts) available for central MRD assessment;~* Subject has provided written informed consent prior to any screening procedure.~Exclusion Criteria:~* Lymphoid blast crisis of chronic myelocytic leukemia (CML);~* Active serious infection not controlled by oral or intravenous antibiotics;~* Active known hepatitis B virus (HBV) or hepatitis C virus (HCV) or positive HIV serology;~* History of acute pancreatitis within 1 year of study or history of chronic pancreatitis;~* Uncontrolled hypertriglyceridemia (triglycerides \> 5.1 µmol/L);~* Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: any history of myocardial infarction, stroke, or revascularization; unstable angina or transient ischemic attack within 6 months prior to enrolment; congestive heart failure within 6 months prior to enrolment or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards; history of clinically significant (as determined by the treating physician) atrial arrhythmia; any history of ventricular arrhythmia; any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism;~* Uncontrolled hypertension (diastolic blood pressure \>90 mmHg; systolic \>140 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control;~* Creatinine levels \> 160 µmol/L or estimated creatinine clearance of \< 50 mL/min;~* GI disease and/or major GI surgery that may significantly alter the absorption of study drug~* Hypersensitivity to the active substance or to any of the excipients, especially galactose intolerance.~* Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib;~* Female patients who are pregnant or breast feeding or patients of childbearing potential not willing to use a highly effective method of contraception during the study and for 3 months following the last dose of study drug;~* Male patients whose sexual partner(s) are women of childbearing potential who are not willing to use a highly effective method of contraception, one of which includes a condom, during the study;~* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention;~* Any concurrent severe and/or uncontrolled medical condition, which could, in the opinion of the investigator, compromise participation in the study;~* Concurrent participation in another clinical study with an investigational medical product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ponatinib plus reduced-intensity chemotherapy (Type: EXPERIMENTAL): ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL

Based on this trial design, predict the completion outcome and termination type (if applicable).